Case Study

De-Risking Phase 3 Rheumatoid Arthritis Trials with Model-Based Meta-Analysis (MBMA)

Learn how Model-based meta-analysis (MBMA) helped optimize Phase 3 trial design, dose selection, and development…

Danielle Pillsbury2026 年 8 月 28 日

Blog

The five drug development questions that bring sponsors to pharmacometrics

Sponsors rarely come to pharmacometrics because they need a model. They come with a development…

Rik de Greef2026 年 8 月 24 日

Webinar

Beyond Trial and Error: Model-Informed Formulation Development in Practice

Siri Kalyan Chirumamilla2026 年 8 月 24 日

Fact Sheet

Model-Based Meta-Analysis (MBMA): Real-World Examples

See real-world examples of how model-based meta-analysis (MBMA) uses existing clinical evidence to predict trial…

Certara2026 年 8 月 24 日

Webinar

How to Choose Your First-in-Human Dose Approach

Certara2026 年 8 月 17 日

Blog

MBMA data curation: How AI and expert meta-analysts get it right, fast

In MBMA, the data layer is the real bottleneck. See how AI and expert meta-analysts…

Matt Zierhut, PhD MBA2026 年 8 月 14 日

Blog

A model-informed approach to radioligand therapy dosing under Project Optimus

Explore how targeted radionuclide therapy dosing uses QSP, biologically effective dose (BED), and exposure-response modeling…

Hunter Stephens, PhD2026 年 8 月 13 日

White Paper

Managing drug-drug interaction (DDI) risk for patients in clinical trials

Discover how DIDB® helps clinical teams assess drug-drug interaction risk, develop prohibited medication lists, &…

Katie Owens, PhD2026 年 8 月 12 日

On-Demand Webinar

Investor panel: What it takes to build a fundable biotech – with Life Science Nation

Investors, founders, and drug development strategists on what makes an early-stage biotech investable beyond the…

Certara2026 年 8 月 6 日

Publication

Advances and Challenges in Model-Informed Precision Dosing of Antimicrobials for Pediatric Patients

Explore advances in model-informed precision dosing (MIPD) for pediatric antimicrobial therapy, including population PK modeling,…

Certara2026 年 7 月 29 日

药物开发

De-Risking Phase 3 Rheumatoid Arthritis Trials with Model-Based Meta-Analysis (MBMA)

The five drug development questions that bring sponsors to pharmacometrics

Beyond Trial and Error: Model-Informed Formulation Development in Practice

Model-Based Meta-Analysis (MBMA): Real-World Examples

How to Choose Your First-in-Human Dose Approach

MBMA data curation: How AI and expert meta-analysts get it right, fast

A model-informed approach to radioligand therapy dosing under Project Optimus

Managing drug-drug interaction (DDI) risk for patients in clinical trials

Investor panel: What it takes to build a fundable biotech – with Life Science Nation

Advances and Challenges in Model-Informed Precision Dosing of Antimicrobials for Pediatric Patients

订阅时事通讯

快捷链接

解决方案

联系我们